Sean McGarvey, MD
Pulmonary Disease · St Petersburg, FLNPI 1275977274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations.
Across 423 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Intuitive Surgical$1K
- Insmed, Inc.$757
- Actelion Pharmaceuticals US, Inc.$551
- Boehringer Ingelheim$500
- plus $4K from 34 others
Across 7 payments — averaging $8092.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$57K
What the payments were for
- Travel & lodging$7558%
- Food & beverage$8,93691%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 74 | $1,461 |
| AstraZeneca(2 entities) | 71 | $1,253 |
| Intuitive Surgical | 11 | $1,102 |
| Insmed, Inc. | 35 | $757 |
| Actelion Pharmaceuticals US, Inc. | 25 | $551 |
| Boehringer Ingelheim | 25 | $500 |
| Grifols USA, LLC | 15 | $366 |
| Regeneron Healthcare Solutions, Inc. | 14 | $357 |
| United Therapeutics Corporation | 14 | $353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $316 |
| Shionogi Inc | 17 | $305 |
| Bayer | 13 | $285 |
| Sanofi | 9 | $231 |
| Amgen | 10 | $199 |
| Jazz Pharmaceuticals Inc. | 9 | $197 |
| Harmony Biosciences LLC | 7 | $182 |
| Baxter Healthcare | 9 | $180 |
| Electromed, Inc. | 9 | $125 |
| Mylan Specialty L.p. | 5 | $122 |
| Merck | 5 | $116 |
| Johnson & Johnson | 6 | $104 |
| Gilead | 4 | $90 |
| Covis Pharma GmbH | 4 | $79 |
| AbbVie(2 entities) | 4 | $73 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Vapotherm Inc | 2 | $57 |
| Verona Pharma, Inc. | 2 | $54 |
| Abiomed | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $44 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Eagle Pharmaceuticals, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Novartis | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Ambu Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $18 |
| Inogen, Inc. | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,807 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 176 | $193,685 |
| Dupixent PenDupilumab | 12 | $44,631 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $41,373 |
| Spiriva RespimatTiotropium Bromide | 46 | $37,860 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $25,220 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $18,857 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,728 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $4,875 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 169 | $3,896 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,198 |
| Roflumilast | 16 | $1,748 |
| Ethambutol Hcl | 18 | $1,143 |
| Azithromycin | 49 | $496 |
| Montelukast Sodium | 23 | $271 |
| Prednisone | 66 | $161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,461 | $256,113272 claims |
| Boehringer IngelheimSpiriva Respimat | $500 | $37,86046 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,253 | $33,94968 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in St Petersburg
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.